Vaccine for early Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a vaccine that may help the immune system clear a protein linked to Alzheimer's disease. It is for people who do not have memory problems yet but have signs of the disease in their blood or brain scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 55 and 80 years old.
- You do not have any memory or thinking problems (your thinking is normal).
- You have a blood test or brain scan that shows early signs of Alzheimer's disease.
- You are generally healthy and can have an MRI (a type of brain scan).
- You have not had any previous Alzheimer's vaccines or antibody treatments in the last year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a vaccine that targets tau protein, which is linked to Alzheimer's disease. It is for older adults who have no memory problems yet but have biological signs of early Alzheimer's, to see if the vaccine can prevent or slow down the disease.
This trial tests an experimental vaccine (DUVAX) that targets two proteins linked to Alzheimer's disease: amyloid-beta and tau. It is an early-stage study to check safety and see how the body responds, aiming to prevent or delay the disease.
This trial tests a treatment targeting tau protein buildup in the brain for people with early Alzheimer's. You may join if you have memory or thinking changes but are still living independently, and brain scans show both amyloid and tau clumps.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease. It aims to see if the drug is safe and can help slow memory decline.
This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
Hear when a new Preclinical Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.